Cellectar Biosciences (CLRB) Short Interest Ratio & Short Volume $0.29 -0.02 (-5.44%) (As of 05:46 PM ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Cellectar Biosciences Short Interest DataCellectar Biosciences (CLRB) has a short interest of 2.79 million shares, representing 6.97% of the float (the number of shares available for trading by the public). This marks a 114.62% increase in short interest from the previous month. The short interest ratio (days to cover) is 1.8, indicating that it would take 1.8 days of the average trading volume of 1.19 million shares to cover all short positions.Current Short Interest2,790,000 sharesPrevious Short Interest1,300,000 sharesChange Vs. Previous Month+114.62%Dollar Volume Sold Short$725,400.00Short Interest Ratio1.8 Days to CoverLast Record DateDecember 15, 2024Outstanding Shares41,270,000 sharesFloat Size40,040,000 sharesShort Percent of Float6.97%Today's Trading Volume2,212,380 sharesAverage Trading Volume1,194,537 sharesToday's Volume Vs. Average185% Short Selling Cellectar Biosciences? Sign up to receive the latest short interest report for Cellectar Biosciences and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartCLRB Short Interest Over TimeCLRB Days to Cover Over TimeCLRB Percentage of Float Shorted Over Time Ad Behind the Markets⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Click here for the ticker >>> Cellectar Biosciences Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 12/15/20242,790,000 shares $725,400.00 +114.6%7.0%1.8 $0.26 11/30/20241,300,000 shares $2.00 million +12.1%3.3%3.9 $1.54 11/15/20241,160,000 shares $2.16 million -37.0%2.9%3.6 $1.86 10/31/20241,840,000 shares $3.75 million -6.1%4.7%7.5 $2.04 10/15/20241,960,000 shares $4.00 million -10.9%5.7%6.2 $2.04 9/30/20242,200,000 shares $4.71 million +35.8%6.3%4.6 $2.14 Get the Latest News and Ratings for CLRB and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Cellectar Biosciences and its competitors with MarketBeat's FREE daily newsletter. 9/15/20241,620,000 shares $3.45 million -37.0%4.7%3 $2.13 8/31/20242,570,000 shares $5.65 million +0.8%7.4%4.6 $2.20 8/15/20242,550,000 shares $5.18 million -10.2%7.4%4.3 $2.03 7/31/20242,840,000 shares $6.11 million +27.9%8.2%4.5 $2.15 7/15/20242,220,000 shares $5.68 million -2.2%6.4%3.4 $2.56 6/30/20242,270,000 shares $5.68 million -4.2%6.5%3.8 $2.50 6/15/20242,370,000 shares $7.63 million +9.2%6.8%3.5 $3.22 5/31/20242,170,000 shares $6.71 million -4.4%6.3%2.8 $3.09 5/15/20242,270,000 shares $7.63 million -11.0%6.5%2.4 $3.36 4/30/20242,550,000 shares $7.88 million +16.4%7.9%2.7 $3.09 4/15/20242,190,000 shares $7.27 million -13.4%7.5%2 $3.32 3/31/20242,530,000 shares $10.07 million +34.6%8.7%1.4 $3.98 3/15/20241,880,000 shares $6.54 million -6.5%16.9%1.1 $3.48 2/29/20242,010,000 shares $7.88 million -15.2%17.0%1.2 $3.92 2/15/20242,370,000 shares $8.51 million +25.4%20.1%1.6 $3.59 1/31/20241,890,000 shares $7.39 million +13.2%17.2%1.4 $3.91 1/15/20241,670,000 shares $5.86 million +208.6%15.2%1.5 $3.51 12/31/2023541,100 shares $1.50 million -9.8%4.9%0.6 $2.77 12/15/2023599,900 shares $1.59 million -11.4%5.5%3.2 $2.65 11/30/2023676,700 shares $1.67 million -15.4%6.7%3.9 $2.47 11/15/2023800,100 shares $1.58 million -7.2%6.9%1.1 $1.98 10/31/2023861,800 shares $2.09 million +3.2%9.2%1.3 $2.42 10/15/2023835,300 shares $2.16 million +25.8%8.9%1.3 $2.59 9/30/2023664,100 shares $1.75 million +37.7%7.1%1 $2.64 9/15/2023482,200 shares $1.07 million +238.4%5.2%0.8 $2.21 8/31/2023142,500 shares $252,225.00 -1.8%1.6%0.2 $1.77 8/15/2023145,100 shares $248,121.00 -9.3%1.6%5.7 $1.71 7/31/2023159,900 shares $311,805.00 +15.0%1.7%4.8 $1.95 7/15/2023139,100 shares $255,944.00 +8.9%1.5%3.7 $1.84 6/30/2023127,700 shares $249,015.00 +18.5%1.4%3.3 $1.95 6/15/2023107,800 shares $220,990.00 +29.4%1.2%2.7 $2.05 5/31/202383,300 shares $129,948.00 +2.7%0.9%2.2 $1.56 5/15/202381,100 shares $111,918.00 -7.4%0.9%1.4 $1.38 4/30/202387,600 shares $134,904.00 +25.5%1.0%1.4 $1.54Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong (Ad)Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. 4/15/202369,800 shares $97,720.00 +47.3%0.8%1.2 $1.40 3/31/202347,400 shares $67,782.00 +4.2%0.5%0.8 $1.43 3/15/202345,500 shares $69,160.00 +237.0%0.5%0.7 $1.52 2/28/202313,500 shares $21,060.00 -49.6%0.2%0.2 $1.56 2/15/202326,800 shares $44,656.84 +8.1%0.3%0.5 $1.67 1/31/202324,800 shares $37,448.00 -40.0%0.3%0.5 $1.51 1/15/202341,300 shares $70,416.50 +50.7%0.5%0.7 $1.71 12/30/202227,400 shares $46,854.00 +144.6%0.3%0.5 $1.71 12/15/202211,200 shares $15,344.00 -9.7%0.1%0.2 $1.37 11/30/202212,400 shares $23,312.00 +53.1%0.1%0.3 $1.88 11/15/20228,100 shares $15,309.00 -16.5%0.1%0.2 $1.89 10/31/20229,700 shares $19,594.00 +61.7%0.1%0.3 $2.02 10/15/20226,000 shares $12,540.00 -1.6%0.1%0.2 $2.09 9/30/20226,100 shares $20,496.00 -28.2%0.1%0.2 $3.36 9/15/20228,500 shares $40,460.00 +6.3%0.2%0.4 $4.76 8/31/20228,000 shares $43,872.00 -64.8%0.1%0.3 $5.48 8/15/202222,700 shares $141,875.00 +59.9%0.4%0.9 $6.25 7/31/202214,200 shares $55,664.00 +647.4%0.3%0.6 $3.92 7/15/20221,900 shares $8,168.08 +111.1%N/A0.1 $4.30 6/30/20229,200 shares $3,716.80 -55.3%0.2%0.1 $0.40 6/15/202220,600 shares $7,698.22 -61.5%0.4%0.1 $0.37 5/31/202253,500 shares $21,935.00 +2.9%N/A0.3 $0.41 5/15/202252,000 shares $19,760.00 +112.2%N/A0.3 $0.38 4/30/202224,500 shares $13,107.50 -55.7%N/A0.1 $0.54 4/15/202255,300 shares $38,079.58 -74.2%N/A0.3 $0.69 3/31/2022214,700 shares $147,670.66 +70.1%N/A1.1 $0.69 3/15/2022126,200 shares $59,440.20 +10.8%N/A0.5 $0.47 2/28/2022113,900 shares $58,145.95 -43.1%N/A0.4 $0.51 2/15/2022200,100 shares $110,455.20 -14.4%N/A0.6 $0.55 1/31/2022233,800 shares $140,280.00 +283.9%N/A0.7 $0.60 1/15/202260,900 shares $42,563.01 +138.8%N/A0.2 $0.70 12/31/202125,500 shares $16,932.00 -74.6%N/A0.1 $0.66 12/15/2021100,500 shares $68,048.55 -32.7%N/A0.3 $0.68 11/30/2021149,300 shares $103,166.30 +112.1%N/A0.4 $0.69 11/15/202170,400 shares $59,368.32 -27.9%N/A0.2 $0.84 10/29/202197,700 shares $84,217.40 -38.4%N/A0.2 $0.86 10/15/2021158,700 shares $145,543.77 -85.2%N/A0.3 $0.92 9/30/20211,070,000 shares $989,750.00 +2.9%N/A1.4 $0.93 9/15/20211,040,000 shares $1.02 million -4.6%N/A1.2 $0.98 8/31/20211,090,000 shares $1.11 million -16.2%N/A1.1 $1.02 8/13/20211,300,000 shares $1.13 million -13.3%N/A1.3 $0.87 7/30/20211,500,000 shares $1.64 million -5.7%3.2%1.8 $1.09 7/15/20211,590,000 shares $1.67 million +40.7%3.4%2.1 $1.05 6/30/20211,130,000 shares $1.34 million -26.1%2.4%1.6 $1.19 6/15/20211,530,000 shares $2.00 million -12.1%3.2%2.6 $1.31 5/28/20211,740,000 shares $2.85 million +4.8%3.7%2.5 $1.64 5/14/20211,660,000 shares $2.08 million -11.7%N/A1.9 $1.25 4/30/20211,880,000 shares $2.91 million +2.2%N/A1.4 $1.55 4/15/20211,840,000 shares $2.74 million -13.2%N/A1.1 $1.49 3/31/20212,120,000 shares $3.26 million -1.4%N/A1.1 $1.54Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong (Ad)Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. 3/15/20212,150,000 shares $4.19 million -9.3%N/A0.9 $1.95 2/26/20212,370,000 shares $4.67 million +2.6%N/A0.9 $1.97 2/12/20212,310,000 shares $5.73 million +4.1%N/A0.8 $2.48 1/29/20212,220,000 shares $3.95 million -1.3%N/A0.9 $1.78 1/15/20212,250,000 shares $4.61 million -11.1%N/A1.1 $2.05 12/31/20202,530,000 shares $5.44 million -4.2%N/A1.4 $2.15 12/15/20202,640,000 shares $5.46 million +161.4%N/A1.7 $2.07 11/30/20201,010,000 shares $1.24 million -3.8%N/A1.1 $1.23 11/15/20201,050,000 shares $1.19 million -2.8%N/A3.9 $1.13 10/30/20201,080,000 shares $1.29 million +4.9%N/A2.8 $1.19 10/15/20201,030,000 shares $1.30 million -1.0%N/A1.6 $1.26 9/30/20201,040,000 shares $1.29 million +1.0%N/A1.4 $1.24 9/15/20201,030,000 shares $1.28 million -8.0%N/A1.2 $1.24 8/31/20201,120,000 shares $1.33 million +6.7%N/A1.2 $1.19 8/14/20201,050,000 shares $1.50 million -6.3%N/A0.8 $1.43 7/31/20201,120,000 shares $1.69 million +284.2%N/A1 $1.51 7/15/2020291,500 shares $411,015.00 +213.4%N/A0.3 $1.41 6/30/202093,000 shares $120,900.00 +54.7%N/A0.1 $1.30 6/15/202060,100 shares $70,918.00 -94.1%N/A0.1 $1.18 5/29/20201,010,000 shares $1.53 million +1,681.3%N/A2 $1.51 5/15/202056,700 shares $82,215.00 +6,200.0%0.7%0.4 $1.45 4/30/2020900 shares $1,535.40 -76.3%0.0%0 $1.71 4/15/20203,800 shares $6,213.76 -92.9%0.0%0 $1.64 3/31/202053,300 shares $77,818.00 -86.3%0.6%0.3 $1.46 3/13/2020388,100 shares $539,459.00 -9.2%4.3%4.9 $1.39 2/28/2020427,200 shares $508,368.00 +13.3%4.8%2.5 $1.19 2/14/2020377,100 shares $757,971.00 +6.3%4.2%2.2 $2.01 1/31/2020354,900 shares $798,525.00 +13.8%4.0%2.9 $2.25 1/15/2020311,900 shares $842,130.00 +88.9%3.4%2.5 $2.70 12/31/2019165,100 shares $432,562.00 -30.4%1.8%1.3 $2.62 CLRB Short Interest - Frequently Asked Questions What is Cellectar Biosciences' current short interest? Short interest is the volume of Cellectar Biosciences shares that have been sold short but have not yet been covered or closed out. As of December 15th, investors have sold 2,790,000 shares of CLRB short. 6.97% of Cellectar Biosciences' shares are currently sold short. Learn More on Cellectar Biosciences' current short interest. What is a good short interest ratio for Cellectar Biosciences? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CLRB shares currently have a short interest ratio of 2.0. Learn More on Cellectar Biosciences's short interest ratio. What is a good short interest percentage for Cellectar Biosciences? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 6.97% of Cellectar Biosciences' floating shares are currently sold short. Is Cellectar Biosciences' short interest increasing or decreasing? Cellectar Biosciences saw a increase in short interest during the month of December. As of December 15th, there was short interest totaling 2,790,000 shares, an increase of 114.6% from the previous total of 1,300,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Cellectar Biosciences' float size? Cellectar Biosciences currently has issued a total of 41,270,000 shares. Some of Cellectar Biosciences' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Cellectar Biosciences currently has a public float of 40,040,000 shares. How does Cellectar Biosciences' short interest compare to its competitors? 6.97% of Cellectar Biosciences' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Cellectar Biosciences: Gain Therapeutics, Inc. (1.33%), Cardio Diagnostics Holdings, Inc. (9.53%), Achilles Therapeutics plc (0.24%), Passage Bio, Inc. (3.31%), Estrella Immunopharma, Inc. (0.14%), CASI Pharmaceuticals, Inc. (1.11%), Q32 Bio Inc. (24.19%), Clene Inc. (1.97%), Surrozen, Inc. (1.90%), ImmuCell Co. (0.23%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.70 billion), Charter Communications, Inc. ($4.32 billion), Spotify Technology S.A. ($4.06 billion), Canadian Natural Resources Limited ($3.45 billion), Reddit, Inc. ($2.79 billion), International Paper ($2.70 billion), Cencora, Inc. ($2.27 billion), SoFi Technologies, Inc. ($2.21 billion), Lululemon Athletica Inc. ($2.13 billion), and Rivian Automotive, Inc. ($2.05 billion). View all of the most shorted stocks. What does it mean to sell short Cellectar Biosciences stock? Short selling CLRB is an investing strategy that aims to generate trading profit from Cellectar Biosciences as its price is falling. CLRB shares are trading down $0.02 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Cellectar Biosciences? A short squeeze for Cellectar Biosciences occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CLRB, which in turn drives the price of the stock up even further. How often is Cellectar Biosciences' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CLRB, twice per month. The most recent reporting period available is December, 15 2024. More Short Interest Resources from MarketBeat Related Companies Gain Therapeutics Short Interest Cardio Diagnostics Short Interest Achilles Therapeutics Short Interest Passage Bio Short Interest Estrella Immunopharma Short Interest CASI Pharmaceuticals Short Interest Q32 Bio Short Interest Clene Short Interest Surrozen Short Interest ImmuCell Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CLRB) was last updated on 12/30/2024 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored>>>RE: Buy this Stock before Trump Takes Office!To make sure everyone has the opportunity to get in, closes for good at midnight on January 1st, we're lowerin...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectar Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectar Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
